SIMBRINZA

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Mexico, Nigeria, Netherlands, Poland, Romania, Singapore, Turkey, United Kingdom, United States

Active ingredients

The drug SIMBRINZA contains a combination of these active pharmaceutical ingredients (APIs):

1 Brinzolamide
UNII 9451Z89515 - BRINZOLAMIDE

Brinzolamide is an inhibitor of carbonic anhydrase II (CA-II). Carbonic anhydrase (CA) is an enzyme found in many tissues of the body, including the eye. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humour secretion resulting in a reduction in intraocular pressure (IOP) which is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss.

Read about Brinzolamide
2 Brimonidine
UNII 4S9CL2DY2H - BRIMONIDINE TARTRATE

Brimonidine is an alpha2-adrenergic receptor agonist that is 1000-fold more selective for the alpha2-adrenoceptor than the alpha1-adrenoreceptor. This selectivity results in no mydriasis and the absence of vasoconstriction in microvessels associated with human retinal xenografts.

Read about Brimonidine

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
SIMBRINZA Eye drops, suspension (eye drops) European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
S01EC54 S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EC Carbonic anhydrase inhibitors
Discover more medicines within S01EC54

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 10536M, 10547D
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 526517050089107, 526517050089207
Country: CA Health Products and Food Branch Identifier(s): 02435411
Country: EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria Identifier(s): 1345-MEE-0915
Country: EE Ravimiamet Identifier(s): 1657694, 1657706
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 114933001
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 387012, 472984
Country: FR Base de données publique des médicaments Identifier(s): 64880296
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 249969
Country: HK Department of Health Drug Office Identifier(s): 64944
Country: IE Health Products Regulatory Authority Identifier(s): 50805
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 7977
Country: IT Agenzia del Farmaco Identifier(s): 043532011, 043532023
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1073921, 1073922
Country: MX Comisión Federal para la Protección contra Riesgos Sanitarios Identifier(s): 126M2017
Country: NG Registered Drug Product Database Identifier(s): B4-9101
Country: NL Z-Index G-Standaard, PRK Identifier(s): 120197
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100317780
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W64462001
Country: SG Health Sciences Authority Identifier(s): 15085P
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699504710175
Country: US FDA, National Drug Code Identifier(s): 0065-4147, 0078-0904

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.